A 62-year-old man with a prior myocardial infarction (secondary prevention) has LDL cholesterol of 110 mg/dL on atorvastatin 80 mg daily. His lipid panel also shows elevated lipoprotein(a) [Lp(a)] at 85 nmol/L. Which agent should be added to further reduce cardiovascular risk in this very-high-risk patient?

Explanation

## Secondary Prevention: Intensifying LDL Lowering Beyond Statin Monotherapy **Key Point:** In secondary prevention (post-MI patients), LDL goals are <70 mg/dL or even <55 mg/dL for very-high-risk patients. When statin monotherapy does not achieve goal, PCSK9 inhibitors are the preferred add-on agents due to robust cardiovascular outcome data and efficacy in reducing both LDL and Lp(a). ### Clinical Context - Prior MI = secondary prevention (very high ASCVD risk) - Current LDL 110 mg/dL on high-intensity statin = above goal - Elevated Lp(a) = independent cardiovascular risk factor; not effectively lowered by statins alone ### PCSK9 Inhibitors: Mechanism and Evidence **High-Yield:** PCSK9 inhibitors (evolocumab, alirocumab, inclisiran) block the degradation of LDL receptors, allowing more receptors to remain on hepatocyte surfaces and increase LDL clearance. - Reduce LDL by 50–60% when added to statin - Also reduce Lp(a) by 25–30% - Trials (FOURIER, ODYSSEY Outcomes) show 15–20% reduction in ASCVD events in secondary prevention ### Comparison of Agents for LDL Intensification | Agent | Mechanism | LDL Reduction | Lp(a) Reduction | First-Line Add-On? | |-------|-----------|---------------|-----------------|-------------------| | **PCSK9 inhibitor** | Blocks PCSK9 protein; ↑ LDL receptor recycling | 50–60% | 25–30% | **Yes** | | **Inclisiran** | siRNA; inhibits PCSK9 mRNA | 50–55% | 25–30% | No (newer, limited access) | | **Niacin** | ↑ HDL, ↓ VLDL/TG; modest LDL ↓ | 15–25% | Minimal | No (GI side effects, limited benefit) | | **Fenofibrate** | PPAR-α agonist; ↓ TG, modest ↑ HDL | Minimal | Minimal | No (TG-focused; not for LDL) | **Clinical Pearl:** Inclisiran is a newer PCSK9 inhibitor (given as subcutaneous injection every 6 months after loading doses) with similar efficacy to monoclonal antibodies but is not yet widely available or preferred as first-line add-on in routine practice; PCSK9 monoclonal antibodies (evolocumab, alirocumab) remain the standard. **Mnemonic:** **PCSK9-I = Post-MI, Can't reach goal, Statin alone Kinda insufficient → 9 (PCSK9) Inhibitor **Warning:** Niacin and fenofibrate are NOT appropriate here—niacin has fallen out of favor due to GI intolerance and lack of additional ASCVD benefit beyond LDL lowering, and fenofibrate is a triglyceride-focused agent, not effective for LDL reduction.